Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Targeted metabolomics provides an approach to quantify metabolites involved in specific molecular pathways. We applied an electrochemistry-based, targeted metabolomics platform to define changes in tryptophan, tyrosine, purine and related pathways in the depressed and remitted phases of major depressive disorder (MDD). Biochemical profiles in the cerebrospinal fluid of unmedicated depressed (n = 14; dMDD) or remitted MDD subjects (n = 14; rMDD) were compared against those in healthy controls (n = 18; HC). The rMDD group showed differences in tryptophan and tyrosine metabolism relative to the other groups. The rMDD group also had higher methionine levels and larger methionine-to-glutathione ratios than the other groups, implicating methylation and oxidative stress pathways. The dMDD sample showed nonsignificant differences in the same direction in several of the metabolic branches assessed. The reductions in metabolites associated with tryptophan and tyrosine pathways in rMDD may relate to the vulnerability this population shows for developing depressive symptoms under tryptophan or catecholamine depletion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The same group of patients also showed changes in the methionine-to-glutathione ratio, indicating alterations in OS and methylation.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [467]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An analysis of the tryptophan, tyrosine, purine pathways, and associated pathways revealed that in patients in remission, methionine levels were higher, while tryptophan and tyrosine levels were lower.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [467]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The levels of these same metabolites were altered in MDD patients who were not taking medication, although not to a significant degree. 467”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [467]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametrics: Statistical Methods Based on Ranks
Mergenthaler, M. J., & Lehmann, E. L. (1979) · Technometrics · doi:10.2307/1268531 · Cited by 3,329
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307
Limbic-cortical dysregulation: a proposed model of depression
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.471 · Cited by 1,585
Discovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Self-citationMetabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 670
Self-citationGawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594
GABAergic dysfunction in mood disorders
Brambilla, P., Perez, J., Barale, F., Schettini, G., & Soares, J. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001362 · Cited by 553
The implications of human metabolic network topology for disease comorbidity
Lee, D.-S., Park, J., Kay, K. A., Christakis, N. A., Oltvai, Z. N., & Barabási, A.-L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802208105 · Cited by 495
Interferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Stahl, S. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0103 · Cited by 489
Research works printed but not linked: 3
- Delgado, P. L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 61 Suppl 6, 7–11 (2000).
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Washington, DC American Psychiatric Association; 1994.
- First, M. B., Spitzer, R. L., Gibbon, M. & William, J. B. W. Structured Clinical Interview fpr DSM-IV-TR Axis 1 disorders, Research Version, Patient Edition (SCID-I/P) New York, NY: New York State Psychiatric Institute, Biometric research; 2002. 73 Maxwell, M. (Bethesda, MD, 1992).
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Effects of pre-analytical processes on blood samples used in metabolomics studies
Yin, P., Lehmann, R., & Xu, G. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8565-x · Cited by 278
Savitz, J., Drevets, W. C., Wurfel, B. E., Ford, B. N., Bellgowan, P. S. F., Victor, T. A., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.02.007 · Cited by 209
“Further, a reduction in the 5-hydroxyindoleacetic acid to kynurenine ratio was found in the cerebrospinal fluid of unmedicated rMDD patients compared with both dMDD patients and HCs, suggesting greater shunting of TRP away from serotonin synthesis towards the kynurenine metabolic pathway (Kaddurah-Daouk et al., 2012).”
ResultSelf-citationPharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology
Kaddurah-Daouk, R., & Weinshilboum, R. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.217 · Cited by 188
Self-citationThe Glutathione System: A New Drug Target in Neuroimmune Disorders
Morris, G., Anderson, G., Dean, O., Berk, M., Galecki, P., Martin-Subero, M., & Maes, M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8705-x · Cited by 187
“3 months without medication to be included [250].”
BackgroundResultOxidative stress markers in affective disorders
Siwek, M., Sowa-Kućma, M., Dudek, D., Styczeń, K., Szewczyk, B., Kotarska, K., Misztak, P., Pilc, A., Wolak, M., & Nowak, G. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71517-2 · Cited by 142
Purine metabolism is dysregulated in patients with major depressive disorder
Ali-Sisto, T., Tolmunen, T., Toffol, E., Viinamäki, H., Mäntyselkä, P., Valkonen-Korhonen, M., Honkalampi, K., Ruusunen, A., Velagapudi, V., & Lehto, S. M. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.04.017 · Cited by 116
Spatial Metabolomics of the Human Kidney using MALDI Trapped Ion Mobility Imaging Mass Spectrometry
Neumann, E. K., Migas, L. G., Allen, J. L., Caprioli, R. M., de Plas, R. V., & Spraggins, J. M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02051 · Cited by 101
Mousten, I. V., Sørensen, N. V., Christensen, R. H. B., & Benros, M. E. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.0645 · Cited by 108
Martins-de-Souza, D. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/dmartins · Cited by 96
“Unmedicated MDD subjects also showed alterations in these same metabolites, but not to a statistical level.(63)”
MahmoudianDehkordi, S., Ahmed, A. T., Bhattacharyya, S., Han, X., Baillie, R. A., Arnold, M., Skime, M. K., John-Williams, L. S., Moseley, M. A., Thompson, J. W., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01097-6 · Cited by 95
Self-citationDoolin, K., Allers, K. A., Pleiner, S., Liesener, A., Farrell, C., Tozzi, L., O’Hanlon, E., Roddy, D., Frodl, T., Harkin, A., et al. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.019 · Cited by 89
Davyson, E., Shen, X., Gadd, D. A., Bernabeu, E., Hillary, R. F., McCartney, D. L., Adams, M. J., Marioni, R. E., & McIntosh, A. M. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.01.027 · Cited by 87
Short overview on metabolomic approach and redox changes in psychiatric disorders
Erjavec, G. N., Konjevod, M., Perković, M. N., Štrac, D. Š., Tudor, L., Barbas, C., Grune, T., Žarković, N., & Pivac, N. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.002 · Cited by 92
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Bhattacharyya, S., Ahmed, A. T., Arnold, M., Liu, D., Luo, C., Zhu, H., Mahmoudiandehkordi, S., Neavin, D., Louie, G., Dunlop, B. W., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0507-5 · Cited by 77
Self-citationChronic unpredictive mild stress leads to altered hepatic metabolic profile and gene expression
Jia, H., Li, Q., Zhou, C., Yu, M., Yang, Y., Zhang, H., Ding, G., Shang, H., & Zou, Z. (2016) · Scientific Reports · doi:10.1038/srep23441 · Cited by 76
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12494 · Cited by 71
“…is in accord with previous observations that phenylalanine plasma levels are higher in heart failure patients diagnosed with MDD, relative to matched controls (Steffens et al., 2010) and that the tyrosine pathway is compromised in depressed patients (Nordin, 1988; Kaddurah-Daouk et al., 2012).”
BackgroundResultInfluentialSelf-citationAdvances in Biomarkers of Major Depressive Disorder
Huang, T., & Lin, C.-C. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.11.003 · Cited by 77
Xu, M., Tian, P., Zhu, H., Zou, R., Zhao, J., Zhang, H., Wang, G., & Chen, W. (2022) · Nutrients · doi:10.3390/nu14061294 · Cited by 75
“Purines and monoamines can be metabolised concurrently in the brain [21,22].”
BackgroundSelf-citationMedina, S., Domínguez‐Perles, R., Gil, J. I., Ferreres, F., & Gil‐Izquierdo, Á. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867320666131119124056 · Cited by 65
“[109]”
BackgroundMetabolomic Analysis in Brain Research: Opportunities and Challenges
Vasilopoulou, C. G., Margarity, M., & Klapa, M. I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00183 · Cited by 67
Pocivavsek, A., Schwarcz, R. M., & Erhardt, S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000239 · Cited by 73
Deng, F.-L., Pan, J.-X., Zheng, P., Xia, J.-J., Yin, B.-M., Liang, W.-W., Li, Y.-F., Wu, J., Xu, F., Wu, Q.-Y., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s186071 · Cited by 58
“Recent studies of CSF metabolite profiles have identified initial metabolic signatures for a variety of central nervous system (CNS) disorders, including depression, bipolar disorder, and Parkinson’s disease.(11,14,15) These metabolite profiles may potentially be useful as biomarkers in neurological conditions.”
BackgroundOgawa, S., Tsuchimine, S., & Kunugi, H. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.028 · Cited by 51
Motsinger‐Reif, A. A., Zhu, H., Kling, M. A., Matson, W. R., Sharma, S., Fiehn, O., Reif, D. M., Appleby, D. H., Doraiswamy, P. M., Trojanowski, J. Q., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-28 · Cited by 54
“In depression, we have identified changes in neurotransmitter pathways, lipid metabolism and betaoxidation among other changes [31-33], and we were able to demonstrate that a patient’s metabolic profile (metabotype) enables the prediction of response to the antidepressant sertraline [34].”
BackgroundSelf-citationReduced cerebrospinal fluid ethanolamine concentration in major depressive disorder
Ogawa, S., Hattori, K., Sasayama, D., Yokota, Y., Matsumura, R., Matsuo, J., Ota, M., Hori, H., Teraishi, T., Yoshida, S., et al. (2015) · Scientific Reports · doi:10.1038/srep07796 · Cited by 53
Behavioral extremes of trait anxiety in mice are characterized by distinct metabolic profiles
Filiou, M. D., Asara, J. M., Nußbaumer, M., Teplytska, L., Landgraf, R., & Turck, C. W. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.019 · Cited by 49
Dumas, M., & Davidovic, L. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9578-5 · Cited by 49
Metabolomics in Psychiatric Disorders: What We Learn from Animal Models
Humer, E. C., Probst, T., & Pieh, C. (2020) · Metabolites · doi:10.3390/metabo10020072 · Cited by 49
Zacharias, H. U., Hertel, J., Johar, H., Pietzner, M., Lukaschek, K., Atasoy, S., Kunze, S., Völzke, H., Nauck, M. A., Friedrich, N., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01176-0 · Cited by 49
Steen, N. E., Dieset, I., Hope, S., Vedal, T. S. J., Smeland, O. B., Matson, W. R., Kaddurah‐Daouk, R., Agartz, I., Melle, I. S., Djurovic, S., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291719000400 · Cited by 47
“…in both central and peripheral tissues in severe mental disorders and other brain disorders (Yao et al., 2010a, 2010b, 2012; Condray et al., 2011; Kaddurah-Daouk et al., 2012, 2013; Motsinger-Reif et al., 2013; Fazio et al., 2015; Gupta et al., 2016; Rotroff et al., 2016; Zhang et al., 2016).”
BackgroundSelf-citationMocking, R. J. T., Naviaux, J. C., Li, K., Wang, L., Monk, J. M., Bright, A. T., Figueroa, C. A., Schene, A. H., Ruhé, H. G., Assies, J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01182-w · Cited by 43
Suvitaival, T., Mantere, O., Kieseppä, T., Mattila, I. M., Pöhö, P., Hyötyläinen, T., Suvisaari, J., & Orešič, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.222 · Cited by 44
Ogawa, S., Ota, M., Ogura, J., Kato, K., & Kunugi, H. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4743-1 · Cited by 37
Pech, J., Forman, J. L., Kessing, L. V., & Knorr, U. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.031 · Cited by 37
Metabolomics of Major Depressive Disorder: A Systematic Review of Clinical Studies
Costa, L. N. F. G., Carneiro, B. A., Alves, G. S., Silva, D. H. L., Guimaraes, D. F., Souza, L. S., Bandeira, I. D., Beanes, G., Scippa, Â. M., & Quarantini, L. C. (2022) · Cureus · doi:10.7759/cureus.23009 · Cited by 50
“The group in remission also had higher methionine levels and higher methionine/glutathione ratios than the other MDD and control groups, suggesting the involvement of methylation pathways and oxidative stress [11].”
BackgroundResultObrenovich, M. E., Donskey, C. J., Schiefer, I. T., Bongiovanni, R., Li, L., & Jaskiw, G. E. (2018) · Bioanalysis · doi:10.4155/bio-2018-0140 · Cited by 34
Duan, J., & Xie, P. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1772059 · Cited by 34
“Decreased levels of 5-HIAA were also reported in the CSF of MDD patients, using an LC-electrochemistry array (LCECA) [53]; however, these results were not always consistent [54].”
BackgroundResultInfluentialSex and race differences of cerebrospinal fluid metabolites in healthy individuals
Reavis, Z. W., Mirjankar, N., Sarangi, S., Boyle, S. H., Kuhn, C. M., Matson, W. R., Babyak, M. A., Matson, S. A., Siegler, I. C., Kaddurah‐Daouk, R., et al. (2021) · Metabolomics · doi:10.1007/s11306-020-01757-0 · Cited by 31
Self-citationChakraborty, S., Tripathi, S. J., Srikumar, B. N., Raju, T. R., & Rao, B. S. S. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104605 · Cited by 29
Purinergic transmission in depressive disorders
Szopa, A., Socała, K., Serefko, A., Doboszewska, U., Wróbel, A., Poleszak, E., & Właź, P. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107821 · Cited by 26
He, Y., Wang, Y., Wu, Z., Lan, T., Tian, Y., Chen, X., Li, Y., Dang, R., Bai, M., Cheng, K., et al. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00557-8 · Cited by 26
Hung, C., Lin, G., Chiang, M., & Chiu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-95221-1 · Cited by 23
The neural stem cell fate determinant TRIM32 regulates complex behavioral traits
Hillje, A., Beckmann, E., Pavlou, M. A. S., Jaeger, C., Pacheco, M. P., Sauter, T., Schwamborn, J. C., & Lewejohann, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00075 · Cited by 20
Bird, S. S., Sheldon, D. P., Gathungu, R. M., Vouros, P., Kautz, R. A., Matson, W. R., & Kristal, B. S. (2012) · Analytical Chemistry · doi:10.1021/ac302278u · Cited by 21
Self-citationJoshi, M. B., Pai, S., Balakrishnan, A., Bhat, M. K., Kotambail, A., Sharma, P., & Satyamoorthy, K. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.01.031 · Cited by 19
Zhang, L., Zou, W., Huang, Y., Wen, X., Huang, J., Wang, Y., & Sheng, X. (2019) · Disease Markers · doi:10.1155/2019/4264803 · Cited by 20
Boyle, S. H., Matson, W. R., Velazquez, E. J., Samad, Z. Z., Williams, R. B., Sharma, S., Thomas, B., Wilson, J. L., O’Connor, C. M., & Jiang, W. (2014) · Metabolomics · doi:10.1007/s11306-014-0718-y · Cited by 17
“…(i.e. Pre- to post-stress change) was effected by applying the Bonferroni correction to alpha = .05 separately for each pathway (i.e. tyrosine, tryptophan, purine, one carbon metabolism, and tocopherols), a method used in previous studies utilizing this platform (Kaddurah-Daouk et al. 2012).”
MethodSelf-citationMetabolomics in Depression: What We Learn from Preclinical and Clinical Evidences
Singh, P., Vasundhara, B., Das, N., Sharma, R., Kumar, A., & Datusalia, A. K. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04302-5 · Cited by 21
“Escalated methionine and lowered methionine vs glutathione ratio were observed in remitted ones, which suggests the involvement of oxidation and methylation stress pathways [115].”
Frank, E., Maier, D., Pajula, J., Suvitaival, T., Borgan, F., Butz‐Ostendorf, M., Fischer, A., Hietala, J. A., Howes, O. D., Hyötyläinen, T., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2017.12.001 · Cited by 18
“However, metabolomics has also played an important role in unravelling putative biomarkers and underlying pathways in several other diseases of the central nervous system [36], including major depressive disorder [37,38], Autism spectrum disorder [39], Alzheimer’s [40–43] and Parkinsons [44–46] diseases.”
BackgroundGenomics-based identification of a potential causal role for acylcarnitine metabolism in depression
Milaneschi, Y., Arnold, M., Kastenmüller, G., Dehkordi, S. M., Krishnan, R. R., Dunlop, B. W., Rush, A. J., Penninx, B. W. J. H., & Kaddurah‐Daouk, R. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.070 · Cited by 20
Self-citationInam, M. E., Fernandes, B. S., Salagre, E., Grande, I., Vieta, E., Quevedo, J., & Zhao, Z. (2023) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-2973 · Cited by 28
Wang, T., Yang, J., Zhu, Y., Niu, N., Ding, B., Wang, P., Zhao, H., Li, N., Chao, Y., Gao, S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.114 · Cited by 15
Self-citationLi, Y., Wang, L., Huang, J., Zhang, P., Zhou, Y., Tong, J., Chen, W., Gou, M., Tian, B., Li, W., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1357293 · Cited by 16
Does urinary metabolite signature act as a biomarker of post-stroke depression?
Cai, W., Wang, X., Wei, X.-F., Zhang, J.-R., Hu, C., Ma, W., & Shen, W.-D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.928076 · Cited by 15
“In contrast, patients with depression had reduced metabolites level of DA in the CSF (86) and in the hypothalamus of depression model mouse (87), results of which were consistent with the monoamine hypothesis.”
ResultPellegrini, S., Palumbo, S., Iofrida, C., Melissari, E., Rota, G., Mariotti, V., Anastasio, T., Manfrinati, A., Rumiati, R., Lotto, L., et al. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00156 · Cited by 17
Abramova, O. V., Zorkina, Y., Syunyakov, T., Zubkov, E. A., Ushakova, V. M., Silantyev, A., Soloveva, K., Gurina, O. I., Majouga, A. G., Morozova, A. Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179598 · Cited by 13
“There is a correlation found between purine metabolite concentration levels in spinal fluid and the concentration levels of monoamine metabolites such as homovanillic acid and 5-hydroxyindoleacetic acid, which proves a parallel metabolism of purines and monoamines in brain tissue [63].”
BackgroundMetabolomics in Schizophrenia and Major Depressive Disorder
Petrovchich, I., Sosinsky, A. Z., Konde, A. S., Archibald, A. R., Henderson, D. C., Maletić‐Savatić, M., & Milanovic, S. M. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1400-8 · Cited by 12
“Cerebrospinal fl uid shows reductions in metabolites associated with tryptophan and tyrosine pathways in remitted depression (Kaddurah-Daouk et al., 2012).”
InfluentialAnalytical tools to assess aging in humans: The rise of geri-omics
da Costa, J. P., Rocha‐Santos, T., & Duarte, A. C. (2015) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2015.09.011 · Cited by 10
Berner, J. E., & Acharjee, A. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00066-5 · Cited by 7
“Generalizability of results is statistically implied by dimensional markers of pathophysiology rather than categorical and thus inherently underpowered binary patient groups, e.g., unmedicated depressed vs. remitted depressed (bipolar) groups described in previous metabolomic studies [40].”
ResultSuthar, H., Tanghal, R. B., Chatzi, L., Goodrich, J. A., Morello-Frosch, R. A., & Aung, M. T. (2024) · Current Environmental Health Reports · doi:10.1007/s40572-024-00451-w · Cited by 8
“Cerebrospinal fluid levels of tyrosine, a conditionally essential amino acid, have also been implicated with MDD [56].”
BackgroundLee, S., Mun, S., Lee, Y., Choi, H., Joo, E.-J., Kang, H., & Lee, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1002828 · Cited by 9
Baraniuk, J. N. (2025) · Scientific Reports · doi:10.1038/s41598-025-91324-1 · Cited by 12
“Depression was associated with decreased ethanolamine 67 or reductions in metabolites associated with tryptophan and tyrosine pathways 68 .”
Savitz, J. B., Nugent, A. C., Bellgowan, P. S. F., Wright, N., Tinsley, R., Zarate, C. A., Herscovitch, P., & Drevets, W. C. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.02.004 · Cited by 4
“Consistent with these data, both currently depressed and remitted MDD subjects have markedly decreased levels of the dopamine catabolite, homovanillic acid (HVA) in the cerebrospinal fluid (Asberg et al., 1984; Kaddurah-Daouk, 2012).”
ResultSelf-citationO’Tuathaigh, C. M. P., Mathur, N., O’Callaghan, M. J., MacIntyre, L., Harvey, R. P., Lai, D., Waddington, J. L., Pickard, B. S., Watson, D. G., & Moran, P. M. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw189 · Cited by 4
“72,73 More recent studies have demonstrated structural lipid alterations in brain areas implicated in schizophrenia in patients as well as mice mutant for a schizophrenia risk gene ( G72/G30 ).”
Opportunities and challenges in psychopharmacology
Schulz, P. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.2/pschulz · Cited by 4
Pharmacogenomics and Personalized Medicine in Mood Disorders
Archer, T., Ricci, S., & Ricciardi, M. R. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_16 · Cited by 2
The Classification of Depression: Embracing Phenotypic Heterogeneity in the Era of the RDoC
Ballard, E. D., Henter, I. D., & Zarate, C. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00001-9 · Cited by 6
Self-citationNeuroanatomy and Developing Brain Circuits in Disruptive Mood Dysregulation Disorder
Bos, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-57398-9_4 · Cited by 1
Long, Y., Liu, H., Ban, R., Xu, Z., & Xu, T. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s540467 · Cited by 1
Mu, Y., Ma, R., Wang, Q., Wang, X., Gu, S., & Zuo, H. (2026) · Translational Stroke Research · doi:10.1007/s12975-026-01439-4 · Cited by 1
Ragguett, R., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813176-3.00038-9 · Cited by 1
Fast recontruction of compact context-specific network modelsPreprint
Pacheco, M. P. (2018) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/8xcwa
The Neuroanatomy, Etiopathogenesis, and Novel Therapeutic Targets in Depressive Disorders
Arora, I., Khurana, K., & Kumar, M. (2024) · Current Psychopharmacologye · doi:10.2174/0122115560281804240102054639
Patients and Healthy Volunteers Are Not the Same: The Distinct Responses to Ketamine
Himmelseher, S., & Kochs, E. F. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_15 · Cited by 1
Li, D., Gao, H., Li, J., Tao, L., Shen, W., & Cai, W. (2026) · Complementary Medicine Research · doi:10.1159/000550810
“Other metabolic studies suggest that tyrosine levels in PSD patients are significantly higher than those in nondepressed stroke patients, while DA metabolite levels in cerebro-spinal fluid of depressed patients and hypothalamus of depression model mice are reduced [84, 85].”
Metadata
- Authors
- Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., Guitart, X., Carlson, P. J., Neumeister, A., Zarate, C., Krishnan, R. R., Manji, H. K., & Drevets, W.
- Affiliations
- Duke University (US)
- National Institutes of Health (US)
- Edith Nourse Rogers Memorial Veterans Hospital (US)
- North Carolina State University (US)
- VA Pittsburgh Healthcare System (US)
- National University of Singapore (SG)
- Corresponding author
- Kaddurah-Daouk, Rima
- ORCID
- Venue
- Scientific Reports
- Published
- 2012-09-19
- Volume
- 2
- Issue
- 1
- Pages
- 667-667
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3446657
- OpenAlex
- W1971315623
- Cited by
- 76
- References
- 77
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 9 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 7 · 2014: 6 · 2013: 5 · 2012: 1
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health
- National Institute of Mental Health
- National Institute of General Medical Sciences (R24GM078233)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- major depressive disorder, remission, tryptophan metabolism, tyrosine metabolism, purine metabolism, methionine, methylation, oxidative stress, catecholamine depletion, depression vulnerability
- MeSH terms
- Adult, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Remission, Spontaneous, Severity of Illness Index, Biogenic Monoamines, Multivariate Analysis, Case-Control Studies, Biosynthetic Pathways, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.